To include your compound in the COVID-19 Resource Center, submit it here.

StreptAvax: IDBE began enrollment of its Canadian Phase II trial of StreptAvax in 70 volunteers. An additional 20 volunteers will be given a marketed hepatitis

ID Biomedical Corp. (IDBE; TSE:IDB), Vancouver, B.C.
Product:

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE